4//SEC Filing
Nextech V Oncology S.C.S., SICAV-SIF 4
Accession 0001209191-20-052353
CIK 0001699382other
Filed
Sep 28, 8:00 PM ET
Accepted
Sep 29, 4:49 PM ET
Size
18.0 KB
Accession
0001209191-20-052353
Insider Transaction Report
Form 4
Transactions
- Conversion
Common Stock
2020-09-29+1,768,023→ 1,768,023 total - Conversion
Series D Preferred Stock
2020-09-29−760,267→ 0 total→ Common Stock (760,267 underlying) - Conversion
Common Stock
2020-09-29+760,267→ 2,528,290 total - Conversion
Series C Preferred Stock
2020-09-29−1,768,023→ 0 total→ Common Stock (1,768,023 underlying)
Lips Thomas
Other
Transactions
- Conversion
Common Stock
2020-09-29+760,267→ 2,528,290 total - Conversion
Series C Preferred Stock
2020-09-29−1,768,023→ 0 total→ Common Stock (1,768,023 underlying) - Conversion
Series D Preferred Stock
2020-09-29−760,267→ 0 total→ Common Stock (760,267 underlying) - Conversion
Common Stock
2020-09-29+1,768,023→ 1,768,023 total
Transactions
- Conversion
Series C Preferred Stock
2020-09-29−1,768,023→ 0 total→ Common Stock (1,768,023 underlying) - Conversion
Common Stock
2020-09-29+760,267→ 2,528,290 total - Conversion
Series D Preferred Stock
2020-09-29−760,267→ 0 total→ Common Stock (760,267 underlying) - Conversion
Common Stock
2020-09-29+1,768,023→ 1,768,023 total
Bleyer Dalia
Other
Transactions
- Conversion
Common Stock
2020-09-29+760,267→ 2,528,290 total - Conversion
Common Stock
2020-09-29+1,768,023→ 1,768,023 total - Conversion
Series D Preferred Stock
2020-09-29−760,267→ 0 total→ Common Stock (760,267 underlying) - Conversion
Series C Preferred Stock
2020-09-29−1,768,023→ 0 total→ Common Stock (1,768,023 underlying)
Detournay Philippe
Other
Transactions
- Conversion
Common Stock
2020-09-29+760,267→ 2,528,290 total - Conversion
Common Stock
2020-09-29+1,768,023→ 1,768,023 total - Conversion
Series C Preferred Stock
2020-09-29−1,768,023→ 0 total→ Common Stock (1,768,023 underlying) - Conversion
Series D Preferred Stock
2020-09-29−760,267→ 0 total→ Common Stock (760,267 underlying)
Footnotes (2)
- [F1]The shares of each of the Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
- [F2]The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. Thilo Schroeder is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. Mr. Schroeder is a director of the Issuer and files separate Section 16 reports. Nextech V GP S.a r.l. is the general partner of Nextech V Oncology S.C.S., SICAV SIF. Dalia Bleyer, Philippe Detournay and Thomas Lips are Managers of Nextech V GP S.a r.l. and each of Nextech V GP S.a r.l., Ms. Bleyer and Messrs. Detournay and Lips may be deemed to share voting and investment power with respect to the shares reported herein and disclaim beneficial ownership over such shares, except to the extent of his, her or its respective pecuniary interest therein, if any.
Documents
Issuer
PMV Pharmaceuticals, Inc.
CIK 0001699382
Entity typeother
IncorporatedLuxembourg
Related Parties
1- filerCIK 0001712922
Filing Metadata
- Form type
- 4
- Filed
- Sep 28, 8:00 PM ET
- Accepted
- Sep 29, 4:49 PM ET
- Size
- 18.0 KB